ARTICLE | Company News
Pharmaxis, Synairgen deal
September 7, 2015 7:00 AM UTC
Synairgen and Pharmaxis partnered to develop a lysyl oxidase-like 2 (LOXL2) inhibitor to treat idiopathic pulmonary fibrosis (IPF). Synairgen will provide funding and its BioBank platform of advanced...